- Travel Insurance
- Why Insurancewith?
- Help Centre
- Travel Tips & Advice
- Holiday Extras
A new breast cancer drug is in trials and early indications are that it will offer hope to thousands of people with secondary breast cancer. It has been reported in The Telegraph today that up to 8000 people a year could benefit from this new drug called Everolimus, it has been hailed as one of the biggest advances for breast cancer treatment in years. The drug works by stalling advanced cancer for about four months longer than current treatments.
The drug will be effective for people with oestrogen positive secondary breast cancer. At the moment people with oestrogen positive breast cancer take hormone blocking medication which blocks the production of oestrogen, which either slows down or stops the tumour growth. However, through time the cancer cells become resistant to the drugs and the tumour growth resumes. When this happens the next line of defence is generally chemotherapy, which can have a debilitating effect on the body and life quality.
The trial results are still coming out but the differences comparing 485 women given the drug and the 239 given a dummy pill are clearly marked after just 18 months.
Secondary or advanced breast cancer is incurable, and although this drug is not a cure, it could give people precious extra months with their families and a good quality of life during that time.
At Insurancewith we pride ourselves on keeping up to date on the latest medical breakthrough to ensure that our breast cancer travel insurance policy is relevant to as many people as possible, so we will be following the results of this trial with great interest.